Kalaris Therapeutics, Inc. — Key Metrics
1 years of history · ending 2019-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
Expense Ratios
Working Capital Analysis
ROIC vs WACC
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
—
Book Value Per Share
—
Free Cash Flow Per Share
—
Cash Per Share
—
OCF Per Share
—
Return on Equity
46.3%
Return on Assets
-17.1%
Return on Invested Capital
41.0%
Current Ratio
13.98
Quick Ratio
13.98
Asset Turnover
0.00
R&D / Revenue
9847.3%
SBC / Revenue
1751.5%
Capex / Revenue
205.5%
Working Capital
$118M
Net Current Asset Value
$110M
Invested Capital
$-52M
OCF / Net Income
0.85
FCF / Net Income
0.86
Accruals Ratio (Sloan)
-2.6%
Net Debt
$-126M
Net Debt / EBITDA
4.73
Interest Coverage
—
Cash Coverage
—
Capex Coverage
-59.45
Tangible Common Equity
$-52M
TCE / Total Assets
-36.9%
NOPAT
$-21M
Cash ROIC
39.8%
WC / Revenue
71640.6%
Capex / D&A
17.84
Reinvestment Rate
-1.2%
Book Value 5Y CAGR
—
Stock Price (FY-end)
—
Market Cap
—
P/B Ratio
—
P/TB Ratio
—
Enterprise Value
—
FCF Yield
—
Shareholder Yield
—
R&D Yield
—
Capex Yield
—
Shares Variation (YoY)
—
Beta (5Y)
—
Cost of Equity
—
52W High
—
52W Low
—
Trailing Return 1Y
—
Trailing Return 5Y
—
F-Score (Piotroski)
—
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.